Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis, and understanding the molecular mechanisms underlying its progression is crucial for developing ...

Early and late responders with esophageal squamous cell carcinoma experienced comparable OS benefits with Tevimbra plus chemo ...

Neoadjuvant CRT plus sintilimab yielded a higher pCR rate than neoadjuvant chemo plus sintilimab in patients with locally ...

The safety and short-term efficacy of neoadjuvant chemotherapy in elderly patients with resectable locally advanced esophageal squamous cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with chemoradiotherapy alone in locally advanced ESCC.

Impact of time to surgery on outcomes in patients with advanced esophageal squamous cell carcinoma following neoadjuvant therapy: An exploratory analysis of phase III trial JCOG1109. This is an ASCO ...

In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an ...

Phone calls to follow up with patients with locally advanced esophageal squamous cell carcinoma while at home may reduce AEs ...

New Delhi: Drug major Glenmark Pharmaceutical has got the go-ahead from the Subject Expert Committee (SEC) functional under ...